Statistical Issues in Drug Development

From MaRDI portal
Publication:5445233

DOI10.1002/9780470723586zbMath1165.62086OpenAlexW4299960933MaRDI QIDQ5445233

Stephen Senn

Publication date: 3 March 2008

Full work available at URL: https://doi.org/10.1002/9780470723586




Related Items (19)

Epistemology of causal inference in pharmacology, Towards a framework for the assessment of harmsStatistical Modeling of Clinical Trials (Recruitment and Randomization)Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian DesignE- and R-optimality of block designs for treatment-control comparisonsOptimal approximate designs for comparison with control in dose-escalation studiesRecruitment prediction for multicenter clinical trials based on a hierarchical Poisson–gamma model: Asymptotic analysis and improved intervalsGROUP SEQUENTIAL TESTS WITH OUTCOME-DEPENDENT TREATMENT ASSIGNMENTConfidence intervals for dependent data: equating non-overlap with statistical significanceEnd-to-end drug supply management in multicenter trialsThe assessment of replication success based on relative effect sizeBeyond the two-trials rule: Type-I error control and sample size planning with the sceptical $p$-valueProportional hazards models with random effects to examine centre effects in multicentre cancer clinical trialsThe design of multicentre trialsThe design of multicentre trialsSimulation of clinical trials: a review with emphasis on the design issuesPredictive Hierarchic Modeling of Operational Characteristics in Clinical TrialsOptimal designs for dose-escalation trials and individual allocations in cohortsA Five-Decision Testing Procedure to Infer the Value of a Unidimensional ParameterFriction and Decision Rules in Portfolio Decision Analysis




This page was built for publication: Statistical Issues in Drug Development